On January 9, 2023, local time, the 41st J.P. Morgan Healthcare Conference was held in San Francisco, USA. Due to the COVID-19 pandemic, this conference was still conducted online. During the event, multiple diagnostic and genomics tool companies shared their latest business updates and discussed the future development of the industry. Below is a brief summary of presentations from selected companies. Agilent Technologies CEO Mark McMullen emphasized that cell analysis, genomics, and diagnostics remain the company's priority areas. Additionally, Agilent is expected to invest $725 million to expand its therapeutic nucleic acid manufacturing capabilities.Recently, Agilent Technologies announced that it will invest in one of its therapeutic nucleic acid manufacturing plants to double its production capacity in response to the growing demand in this market. Currently, the therapeutic nucleic acid market is valued at $1 billion and is expected to reach $2.4 billion by 2027. Agilent's investment will be used to add two production lines for the manufacturing of siRNA, antisense oligonucleotides, and CRISPR guide RNA by 2026.Currently, Agilent Technologies has one production line in operation, and the second production line will be operational by mid-2023, potentially adding at least $150 million in revenue, with full production expected to be achieved before the fiscal year ends in September.Agilent Technologies' existing business surpassed the $300 million revenue threshold in fiscal year 2022."We are on track to reach $1 billion in revenue," McMullen said.According to the introduction, Agilent TechnologiesFiscal Year 2022Business in ChinaRealityAn 18% growth was observed.Cell analysis business provided approximately $400 million in revenue in the fiscal year 2022.Enter.Agilent CFO Robert McMahon said that through conversations with existing customers about their future clinical trials, he is confident there is sufficient application demand in this area. "Analyzing the target field of oligonucleotide therapies reveals they are reaching an increasingly broad patient population." Roche CFO Alan Hippe stated in the report that with the growth of the underlying business, sales of COVID-19 are declining. It is expected that COVID-19 sales in 2023 will lose approximately 5 billion Swiss francs (5.42 billion U.S. dollars), accounting for about 8% of total sales.The COVID-19 pandemic has driven higher demand for instrument installations——As of the third quarter of 2022, Roche had installed approximately 2,000 high-throughput Cobas 6800/8800 systems.Hippe stated that these sales have enabled Roche to gain a certain market share in the United States and China.In the Cobas serum business, the expansion of testing services is driving its future growth. More than 100,000 Cobas SWA instruments have been installed, capable of performing over 240 types of tests.Roche is also developing an integrated mass spectrometer and is currently conducting 30 to 40 mass spectrometry tests. Roche considers this instrument a significant market opportunity with a potential market of 2.9 billion Swiss francs. Hippe noted that many mass spectrometry instruments are highly manual and require customized methods.Roche aims to provide a high-throughput system that requires minimal manual work and delivers standardized results.In addition, Roche also has aCombined with immunochemistry and clinical chemistryDesktop AnalyzerUnder development to meet the needs of emerging markets, as well as a next-generation sequencing solution that will integrate with Roche's existing sequencing infrastructure, opening new doors for high-throughput sequencing.Hippe also mentioned that Roche has made significant investments in artificial intelligence and digital health, spending approximately 3 billion Swiss francs annually on digitalization across various fields.Roche has significant financial flexibility to fund its operations and acquisitions, with plans to strengthen its pharmaceuticals and diagnostics businesses.Acquisition. Thermo Fisher Scientific CEO Marc Casper highlighted the company's achievements in 2022 at the conference, including the acquisition of UK-based specialty diagnostics company The Binding Site for £2.25 billion.Casper pointed out,"2022 was one of the best years in our history", and shared the release of multiple products, includingApplied Biosystems SeqStudio Flex Genetic Analyzer and Orbitrap Ascend Tribrid Mass Spectrometer Based on Sanger Sequencing。Looking ahead, Casper expressed "greater excitement about the developments in 2023." Regarding the approximately 3% price increase for customers in 2022, he noted that prices in 2023 "will not return to normal, but will not be as high as in 2022." He revealed that Thermo Fisher Scientific has around $50 billion secured to guarantee its capital deployment capability over the next three years. Guardant Health Co-founder and Co-CEO Helmy Eltoukhy Shares the Company's"Intelligent" Liquid Biopsy PlatformThe deployment, which he called a "quantum leap."This platform combines liquid biopsy with new multimodal chemistry, allowing for the simultaneous examination of genomic and epigenomic data to enhance performance. It is 50 times more sensitive than Guardant360 CDx and expands genomic data coverage at the same commodity cost.Guardant Shield screening test and Guardant Infinity research test have already utilized this technology. Eltoukhy announced that Guardant Reveal will be upgraded to this platform in 2023. This upgrade will be achieved through detectionMore than 1,000 biomarkers"To significantly improve sensitivity," the company also plans to upgrade the rest of its product portfolio.Guardant Health Co-CEO AmirAli Talasaz stated that the company plans to complete the FDA premarket submission for the Guardant Shield test, used in colorectal cancer screening, in the first quarter of 2023, and aims to gain approval and launch the test as an in vitro diagnostic by 2024. Recently released ECLIPSE trial data from Guardant Health shows that the test...Sensitivity of 83%, specificity of 90%The sensitivity for advanced adenomas was 13%. Talasaz stated that although the sensitivity was lower than expected, the data would still support its regulatory approval and Medicare reimbursement.Talasaz introduced, a project involving10,000 PatientsThe multi-site study for the Lung Cancer Shield test was launched in 2022 and will reach its first endpoint in 2025. The test is expected to be submitted to the FDA in 2026. Additionally, Guardant Health is developing Shield panels for other cancer indications, with projections indicating that by 2032, there could be 10 million Shield colorectal cancer screenings annually, potentially generating $5 billion in sales. 10x Genomics CEO Serge Saxonov stated that the company sold over 100 CytAssist devices in the third quarter of 2022. CytAssist was launched in June 2022.Can help prepare standard tissue slides for use with the company's Visium Spatial Transcriptomics platform."This is by far the best way to run Visium and represents the future of the platform," 10x Genomics is working to expand the Visium method to accommodate more tissue types and include more analytes.Saxonov also introduced 10x GenomicsFlex Kit, for its Chromium Single Cell Sample Preparation Instrument.The instrument can fix the sample during collection, solving a limitation people may encounter in single-cell analysis: the need to use live tissue. "Not only that, but we also see it as the new standard for single-cell gene expression analysis," Saxonov stated, noting the platform's high sensitivity allows for multiplex analysis of 128 samples. For the Xenium in situ analysis platform, 10x Genomics is also working on adding more analytes, increasing throughput, and enhancing multiplexing capabilities.In the report, Saxonov introduced that the company's total potential market is as high as 16 billion US dollars. He believed that the cell atlas could be worth 2 billion US dollars, and 10x only has a penetration rate of about 20% in this market. Functional genomics and genetic mechanism research may be worth 2 billion US dollars, and 10x only covers 10% of this market. The broader cell and molecular biology can be regarded as a 5-billion-US-dollar market, but 10x’s penetration rate is only 10%. Finally, translational research is considered a 7-billion-US-dollar market, and 10x believes it has solved less than 5%. Exact Sciences CEO Kevin Conroy highlighted his company's business growth and momentum. He noted,ExactExpected to achieve profitability in 2023, earlier than the previously estimated 2024. In the recently released preliminary financial results, Exact reported a 16% to 17% year-over-year increase in fourth-quarter revenue.Revenue Growth of 18% for the Full Year 2022Conroy stated that this result is sustainable, and some of the key drivers of fourth-quarter growth came from long-term investments, such as brand awareness, product quality, and the commercial team.Conroy pointed out that the penetration rate of Oncotype Dx breast cancer recurrence score is currently very high in the U.S. market, and the company plans to expand the test to more countries with growth opportunities in 2023.Exact Sciences has operations in 90 countries/regions.Currently, Exact Sciences is planning to launch the Oncotype Dx breast cancer recurrence score test in Japan and will work to increase its adoption rate in India and Brazil. The test received approval in Japan in 2021.In addition, Conroy provided more information about the multi-cancer blood test that Exact is developing, indicating that the company might seek FDA approval rather than offering it as a laboratory-developed test. Myriad Genetics Highlighted Three New Products to be Launched in 2023, Covering Women's Health and Oncology Fields.In terms of women's health business, Myriad plans to launch in the third quarter of 2023.FirstGene 4-in-1 Prenatal Screening Test, Covering Non-Invasive Prenatal Screening, Carrier Screening, Fetal Recessive Status, and Fetal-Maternal Blood CompatibilityMyriad Chief Issues Officer Dale Muzzey referred to the test as "Transformative Products in the Field of Reproduction", because it has a faster turnaround time, fewer uncertain fetal recessive genetic test results, and lower costs. According to Muzzey, it covers three times the number of genes as the Unity prenatal screening.FirstGene 4-in-1 Prenatal Screening consists of two parts: NIPT screening for common aneuploidies and carrier screening for common diseases. The fetal gene testing portion examines the fetal genome to determine whether the fetus is affected by or a carrier of certain genetic conditions. The fetal-maternal blood compatibility portion identifies whether the mother requires immunosuppressive therapy. Additionally, this test...Only a blood sample is required, and results can be returned without testing the father.In terms of oncology business, Myriad CEO Paul Diaz said that Myriad is enriching its product portfolio by launching the Precise Liquid molecular profiling test and Precise MRD monitoring.Precise Liquid is a 523-gene comprehensive genomic analysis expected to launch in the second half of 2023.In 2022, Myriad launched Precise Tumor, a test that examines 523 genes and includes RNA analysis to detect gene fusions in solid tumors.Precise MRD Detection Uses Whole Genome Sequencing to Detect Tumors, Monitor Recurrence Earlier, and Help Guide Treatment Decisions. Analyzing the entire genome allows for monitoring more sites, enabling higher sensitivity and earlier recurrence detection for more tumors, which is especially important for tumors without high TMB. Internal data shows,Precise MRD detection demonstrates over 99% sensitivity at a tumor fraction of 0.01% and consistently performs effectively across tumor types such as colorectal cancer, endometrial cancer, and ovarian cancer. Twist Bioscience has entered into a research collaboration with Astellas Pharma to discover antibodies against multiple targets.According to the agreement, Twist will search for antibodies targeting multiple targets identified by Astellas. In addition to upfront payments and specific project research fees, Twist will receive up to $11 million per product upon reaching certain clinical and commercial milestones. Twist will also receive royalties on product sales. Astellas will be responsible for the development, manufacturing, and commercialization of any related products.Twist Bioscience CEO and co-founder Emily Leproust said that the products to be shipped later in 2023 will include what are known as"Fast genes," with a turnaround time faster than existing products. Such a product could open up a market worth $1.4 billion.Twist Bioscience plans to launch a new product by the end of 2023.DNA-Based Data Storage ProductsThe early access program, used for long-term archiving. Leproust stated that archival storage is a $35 million market, with 40% of potential customers wanting to archive for 100 years or longer, and DNA can offer lower costs compared to magnetic tape or digital hard drives. Adaptive Biotechnologies CEO Chad Robins outlined the company’s strategic focus, highlighting two key pillars: minimal residual disease (MRD) testing for blood cancers and immune medicine. Adaptive’s goal isIncrease the penetration of the company's NGS-based ClonoSeq assay in clinical trials and the pharmaceutical market, and drive drug discovery.The MRD testing department of Adaptive Biotechnologies (including ClonoSeq testing for doctors and ClonoSeq trials for pharmaceutical companies)Full-year revenue for 2022 is expected to exceed 80 million US dollars., an increase of 45% from US$56 million in 2021, and it is expected that MRD testing will grow by 50% in 2023.The company's compound annual growth rate from 2022 to 2027 is expected to be between 20% and 30%.Robins stated that the company is also working to expand the use of ClonoSeq in hematological malignancies. Currently, about 30% of ClonoSeq tests use blood samples, which make the test easier to perform. Adaptive will conduct nine studies over the next three years to gather more data on ClonoSeq's blood testing.Adaptive Biotechnologies also plansExpanding the Indications of ClonoSeq to Non-Hodgkin LymphomaApproximately 50% of patients who meet the ClonoSeq testing criteria have non-Hodgkin lymphoma, with 30% suffering from diffuse large B-cell lymphoma. Adaptive Biotechnologies Corporation plans to seek FDA approval for this indication in 2023.In the field of immune medicine, Adaptive aims to drive growth in immune receptor sequencing for pharmaceutical services and in drug discovery areas such as target discovery, T-cell therapy, and antibody therapy. Pharmaceutical companies can use Adaptive's ImmunoSeq solution to assess the immune profile of patients to understand how drugs impact them.Adaptive's drug discovery efforts focus on cancer and autoimmune diseases, with its platform capable of validating new disease-specific drug targets and then identifying immune receptors that can be used to treat these targets. Currently, Adaptive has two T-cell therapy products: one containing T-cell receptors targeting a shared cancer neoantigen, and the other featuring multiple receptors targeting unique tumor neoantigens in individual patients. The first therapy, developed in collaboration with Genentech, a subsidiary of Roche, is seeking FDA Investigational New Drug (IND) approval.1.JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, Bruker, 10x Genomics, Morehttps://www.genomeweb.com/business-news/jp-morgan-healthcare-conference-day-1-guardant-health-exact-sciences-bruker-10x#.Y74elMjwqvM2.JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Agilent, Roche, Seer, Morehttps://www.genomeweb.com/business-news/jp-morgan-healthcare-conference-day-2-thermo-fisher-agilent-roche-seer-more#.Y792osjwqvM3.Myriad Genetics Highlights 2023 Product Launches for Women's Health, Oncology Businesseshttps://www.genomeweb.com/business-news/myriad-genetics-highlights-2023-product-launches-womens-health-oncology-businesses#.Y74rUcjwqvM
| 
